Oncimmune Holdings has signed an autoantibody profiling contract with Dana-Farber Cancer Institute in Boston, Massachusetts. Dana-Farber, a clinical affiliate and research institute of Harvard Medical School, is a cancer research organisation and its cancer hospitals have more than 1,100 therapeutic and non-therapeutic clinical trials in progress. Under this agreement, Oncimmune… Read More
The guest on this podcast is Dr. Joanna Hawryluk, Product Manager for Research Imaging at Olympus Corporation of the Americas located in Waltham, Massachusetts. She discusses automating the cell culture workflow and explains the importance of cell culture workflow in the drug discovery process and how it can be improved… Read More
Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More
Paradigm4 has launched Reveal: Multi-Omics, an app which allows researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across integrated public reference and proprietary datasets. It is built on top of Paradigm4’s SciDB analytics platform, designed for rapid data slicing that enables scientific data modelling,… Read More
BioIVT has moved its London blood donor centre to Imperial College London’s White City Campus, which is four times larger than its previous facility. BioIVT has seven global blood donor centres and supports the work of about 30,000 researchers worldwide. “We are responding to a rapidly… Read More
Thread, a technology and service provider for decentralised clinical trials, has been awarded a Frost & Sullivan award. The company scooped the Frost & Sullivan’s 2021 Customer Value Leadership Award in the decentralised clinical trials industry. “Thread’s innovations via its decentralised trials platform are sure… Read More
Scientists at the Institut Laue-Langevin (ILL), in collaboration with the Paul Scherrer Institut (PSI), the Institut de Biologie Structurale (IBS) and the Australian Nuclear Science and Technology Organisation (ANSTO), have published new data on how the SARS-CoV-2 spike protein interacts with mammalian lung cell membranes, allowing the viral… Read More
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery. The therapy is an engineered molecule called MS21 that causes the degradation of AKT, an enzyme that is overly… Read More
Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of… Read More
This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing… Read More
This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing… Read More
News round-up by DDW’s Megan Thomas for 19 – 23 July DDW’s Megan Thomas rounds up her top five stories this week which facilitate the continuation of vital drug discovery research, from partnerships and funding to successful trials and informative reports. Exscientia accelerates Covid-19 drug discovery using AI Exscientia… Read More
Orbit Discovery has raised US$7.6 million which will be used to accelerate its growth as a provider of peptide discovery services to the biotechnology and pharmaceutical industry. Orbit Discovery’s novel bead-based and microfluidic technology platform enables the screening of peptide libraries for target binding and subsequent activity in cell-based functional… Read More
Bial and Medis have partnered on two of Bial’s proprietary drugs: Zebinix (eslicarbazepine acetate) and Ongentys (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys in Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia,… Read More
Listen to this article on the DDW Podcast: Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than 100 compounds. Read More
Listen to this article on the DDW Podcast: Dr Richard O’Kennedy, Vice-President for Research, Development and Innovation at Qatar Foundation, looks at the global potential within pharmacogenomics. Twenty years on since the first human genome was sequenced, pharmacogenomics has the capacity to significantly change the world of medicine. The term pharmacogenomics… Read More
